ASTRIA THERAPEUTICS INC (ATXS) Stock Price, Quote, News and Overview
NASDAQ:ATXS - Nasdaq - US04635X1028 - Common Stock - Currency: USD
ATXS Quote, Performance and Key Statistics
4.37
-0.74 (-14.48%)
The current stock price of ATXS is 4.37 USD. In the past month the price decreased by -2.89%. In the past year, price decreased by -55.09%.
ATXS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.22 | 331.06B | ||
| AMGN | AMGEN INC | 13.03 | 145.40B | ||
| GILD | GILEAD SCIENCES INC | 12.65 | 121.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.6 | 60.30B | ||
| ARGX | ARGENX SE - ADR | 323.74 | 37.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.10B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.77B | ||
| NTRA | NATERA INC | N/A | 21.14B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.97B | ||
| BIIB | BIOGEN INC | 7.38 | 17.12B |
Related stock screener links
About ATXS
Company Profile
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2015-06-25. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. The company owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.
Company Info
ASTRIA THERAPEUTICS INC
22 Boston Wharf Road, 10th Floor
Boston MASSACHUSETTS US
CEO: Jill C. Milne
Employees: 78
Phone: 16173491971
ASTRIA THERAPEUTICS INC / ATXS FAQ
What is the stock price of ASTRIA THERAPEUTICS INC today?
The current stock price of ATXS is 4.37 USD. The price decreased by -14.48% in the last trading session.
What is the ticker symbol for ASTRIA THERAPEUTICS INC stock?
The exchange symbol of ASTRIA THERAPEUTICS INC is ATXS and it is listed on the Nasdaq exchange.
On which exchange is ATXS stock listed?
ATXS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ASTRIA THERAPEUTICS INC stock?
15 analysts have analysed ATXS and the average price target is 27.03 USD. This implies a price increase of 518.54% is expected in the next year compared to the current price of 4.37. Check the ASTRIA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ASTRIA THERAPEUTICS INC worth?
ASTRIA THERAPEUTICS INC (ATXS) has a market capitalization of 246.60M USD. This makes ATXS a Micro Cap stock.
How many employees does ASTRIA THERAPEUTICS INC have?
ASTRIA THERAPEUTICS INC (ATXS) currently has 78 employees.
What are the support and resistance levels for ASTRIA THERAPEUTICS INC (ATXS) stock?
ASTRIA THERAPEUTICS INC (ATXS) has a resistance level at 6.13. Check the full technical report for a detailed analysis of ATXS support and resistance levels.
Should I buy ASTRIA THERAPEUTICS INC (ATXS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATXS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATXS, evaluating the profitability, health, valuation and growth aspects
- ASTRIA THERAPEUTICS INC (ATXS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ASTRIA THERAPEUTICS INC (ATXS) Sales and EPS estimates to see what analysts future expectations are.
- ASTRIA THERAPEUTICS INC (ATXS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ASTRIA THERAPEUTICS INC (ATXS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ASTRIA THERAPEUTICS INC (ATXS) Stock Chart to make your own analysis
- ASTRIA THERAPEUTICS INC (ATXS) Latest news and press-releases to stay up to date.
Does ASTRIA THERAPEUTICS INC (ATXS) stock pay dividends?
ATXS does not pay a dividend.
When does ASTRIA THERAPEUTICS INC (ATXS) report earnings?
ASTRIA THERAPEUTICS INC (ATXS) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of ASTRIA THERAPEUTICS INC (ATXS)?
ASTRIA THERAPEUTICS INC (ATXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.43).
What is the Short Interest ratio of ASTRIA THERAPEUTICS INC (ATXS) stock?
The outstanding short interest for ASTRIA THERAPEUTICS INC (ATXS) is 6.36% of its float. Check the ownership tab for more information on the ATXS short interest.
ATXS Technical Analysis
ATXS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ATXS. While ATXS has a great health rating, there are worries on its profitability.
ATXS Financial Highlights
Over the last trailing twelve months ATXS reported a non-GAAP Earnings per Share(EPS) of -1.43. The EPS increased by 40.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.53% | ||
| ROE | -29.52% | ||
| Debt/Equity | 0 |
ATXS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to ATXS. The Buy consensus is the average rating of analysts ratings from 15 analysts.